Medivation News (AMEX:MDV)
| Latest Medivation News Headlines | | Date | Time | Source | | | 03/19/2007 | 9:00AM | PRNUS | Medivation Announces Presentation of Full Top-Line Data From Dimebon(TM) Six-Month Trial at Major International Alzheimer's Dise
SAN FRANCISCO, March 19 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that six-month results from its randomized, double-blinded, placebo-controlled Phase 2 efficacy trial of Dimebon(TM) in patients with mild-to-moderate Alzheimer's disease demonstrated that patients treated with Dimebon were... More...>> |
| 03/08/2007 | 4:00PM | PRNUS | Medivation Common Stock Approved for Listing on the Nasdaq Global Market
SAN FRANCISCO, March 8 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that The Nasdaq Listing Qualifications Department has approved the Company's application to list its common stock on The Nasdaq Global Market. The Company's common stock will begin trading on The Nasdaq Global Market under... More...>> |
| 03/05/2007 | 8:00AM | PRNUS | Medivation to Present at Cowen and Company's 27th Annual Healthcare Conference
SAN FRANCISCO, March 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that David Hung, M.D., president and chief executive officer, will present at Cowen and Company's 27th Annual Healthcare Conference on Monday, March 12, at 2:45 p.m. Eastern Time at the Boston Marriott Copley Place in Boston.
Dr... More...>> |
| 02/26/2007 | 8:00AM | PRNUS | Medivation's MDV3100 Shown to Be Effective in a Preclinical Model of Hormone-Refractory Prostate Cancer
- Data Presented in Oral and Poster Presentations at ASCO's Prostate Cancer Symposium -
SAN FRANCISCO, Feb. 26 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that results from a preclinical study suggest that MDV3100, the Company's lead development candidate for hormone-refractory prostate cancer... More...>> |
| 02/16/2007 | 8:00AM | PRNUS | Preclinical Efficacy Data on Medivation's MDV3100 to Be Presented at ASCO-sponsored Prostate Cancer Symposium
SAN FRANCISCO, Feb. 16 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that preclinical efficacy data on MDV3100, a novel small molecule the Company is developing to treat hormone-refractory prostate cancer, will be presented later this month at the Prostate Cancer Symposium, a gathering sponsored... More...>> |
| 02/05/2007 | 8:00AM | PRNUS | Medivation to Present at BIO CEO & Investor Conference 2007
SAN FRANCISCO, Feb. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that David Hung, M.D., president and chief executive officer, will present at the 9th Annual BIO CEO & Investor Conference on Monday, February 12, at 12:30 p.m. Eastern Time at the Waldorf- Astoria Hotel in New York.
Dr. Hung... More...>> |
| 01/30/2007 | 8:00AM | PRNUS | Medivation's Dimebon(TM) Phase 2 Trial Results to be Presented at 8th International Conference on Alzheimer's and Parkinson's Di
SAN FRANCISCO, Jan. 30 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that results of its Phase 2 efficacy study of Dimebon(TM) in Alzheimer's disease will be presented at the 8th International Conference on Alzheimer's and Parkinson's Diseases: Progress and New Perspectives in Salzburg, Austria... More...>> |
| 01/17/2007 | 8:00AM | PRNUS | Medivation Names Lisa Taylor Vice President of Commercial Development
SAN FRANCISCO, Jan. 17 /PRNewswire/ -- Medivation, Inc. (AMEX:MDV) today announced that it has appointed Lisa Taylor as vice president of commercial development. Ms. Taylor is responsible for the Company's market research, market development, communications and pre-launch planning functions.
"Lisa has a strong background... More...>> |
| 12/05/2006 | 8:00AM | PRNUS | Medivation Appoints Sue Wollowitz, Ph.D., Vice President of Chemistry and Manufacturing
SAN FRANCISCO, Dec. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced the appointment of Sue Wollowitz, Ph.D., as vice president, chemistry and manufacturing. Dr. Wollowitz, who has more than 20 years of experience in drug discovery and development, joins Medivation as a member of the senior management... More...>> |
| 12/04/2006 | 2:25PM | PRNUS | Medivation, Inc. Adopts Shareholder Rights Plan
SAN FRANCISCO, Dec. 4 /PRNewswire/ -- Medivation, Inc. (AMEX:MDV) announced today that its Board of Directors has adopted a Shareholder Rights Plan.
"This plan is designed to enhance the Board's ability to protect shareholders against unsolicited attempts to acquire control of the Company that do not offer an adequate... More...>> |
| 11/15/2006 | 8:30AM | PRNUS | Medivation Provides Clinical Development Update for Its Three Programs
--Conference Call Scheduled for 1:00 p.m. EST Today--
SAN FRANCISCO, Nov. 15 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced updated clinical development plans and milestones for its three programs in Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer.
Dimebon(TM... More...>> |
| 11/08/2006 | 4:00PM | PRNUS | Medivation to Host Conference Call on November 15 to Provide Clinical Development Update for Lead Product Candidate Dimebon(TM)
SAN FRANCISCO, Nov. 8 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that it will hold a conference call to provide an update on the clinical development plan and milestones for its lead product candidate Dimebon(TM). David Hung, M.D., president and chief executive officer, will host the call... More...>> |
| 11/01/2006 | 8:00AM | PRNUS | Medivation Announces Participation in Rodman & Renshaw 8th Annual Healthcare Conference
SAN FRANCISCO, Nov. 1 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that David Hung, M.D., president and chief executive officer, will present at the Rodman & Renshaw 8th Annual Healthcare Conference on Monday, November 6, at 3:30 p.m. Eastern Time at the New York Palace Hotel.
Dr. Hung will... More...>> |
| 10/19/2006 | 8:00AM | PRNUS | Medivation Begins Phase 1-2a Trial of Dimebon(TM) in Huntington's Disease
Company to Present at BIO InvestorForum 2006 Today at 9:40 a.m. Pacific Time
SAN FRANCISCO, Oct. 19 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that patient dosing has begun for its Phase 1-2a clinical trial of Dimebon(TM) to treat Huntington's disease.
"The initiation of our first clinical... More...>> |
| 10/16/2006 | 8:00AM | PRNUS | Medivation to Present Additional Alzheimer's Disease Data at BIO Investor Forum 2006
SAN FRANCISCO, Oct. 16 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that it will present additional data from the recently completed Alzheimer's disease clinical trial of the Company's investigational drug Dimebon(TM) at the BIO Investor Forum 2006. David Hung, M.D., president and chief executive... More...>> |
|
|
|